. Author manuscript; available in PMC: 2016 Apr 9.

Published in final edited form as: J Infect Dis. 2009 Jun 1;199(11):1648–1656. doi: 10.1086/598980

Table 1.

Patient characteristics 18-24 months before enrollment.

Patient	Plasma HIV RNA history, copies/mL^a	Plasma HIV RNA at enrollment, copies/mL	CD4⁺ T cell count,^bcells/mm³		CD4⁺ T cell count at enrollment, cells/mm³	CD4⁺ T cell count at enrollment, %	ART regimen at enrollment, (months on ART regimen]	ART regimen at change	Sex; age, years
Patient	Plasma HIV RNA history, copies/mL^a	Plasma HIV RNA at enrollment, copies/mL	Highest count	Nadir count	CD4⁺ T cell count at enrollment, cells/mm³	CD4⁺ T cell count at enrollment, %	ART regimen at enrollment, (months on ART regimen]	ART regimen at change	Sex; age, years
1	BLD	<50	1141	311	311	20	ddl, TDF, 3TC (18)	TDF, 3TC, ABC, ATZ, RTV	F; 51
2	BLD	<50	746	272	272	24	ddl, TDF, 3TC (24)	EFV, AZT, 3TC	M; 66
3	BLD	<50	692	174	219	19	ddl, ABC, NVP (29)	ddl, ABC, NVP, ATZ	F; 39
4	BLD	<50	360	182	193	16	ddl, TDF, EFV, d4T (7)	ddl, TDF, EFV	M; 34
All patients, median	...	...	719	227	246	...	...	...	...

NOTE. ABC, abacavir; ART, combination antiretroviral therapy; ATZ, atazanavir; AZT, zidovudine; BLD, below the limit of detection for the assay; d4T, stavudine; ddl, didanosine; EFV, efavirenz; HIV, human immunodeficiency virus; NVP, nevirapine; RTV, ritonavir, TDF, tenofovir; 3TC, lamivudine.

These assays were performed in the 18-24 months before enrollment and represent values of <50 or <400 copies/mL, depending on the assay.

The highest and nadir CD4⁺ T cell counts were obtained during an 18-24-month period before enrollment.